11-脱氢血栓素B_2与阿司匹林反应性及在冠心病中的应用被引量：5

下载PDF

导出

摘要 11-脱氢血栓素B_2（11-dehydro-thromboxane B_2,11dh TXB_2）是血栓烷素A2（thromboxane A2,TX_A2）的终末代谢产物,主要经肾排出。TXA_2则是花生四烯酸在环氧合酶（cyclooxygenase,COX）作用下产生的具有促血小板聚集、收缩血管等生物活性作用的物质,在血栓形成过程中有重要作用。阿司匹林能通过不可逆地抑制COX-1活性,减少TXA_2合成,从而抑制血小板聚集及其在冠状动脉粥样硬化性心脏病（冠心病）发展和急性冠状动脉综合征（acute coronary syndrome,ACS）发生中的作用。

作者刘晓妍杨帆龚艳君

机构地区北京大学第一医院心内科

出处《中国介入心脏病学杂志》 2018年第3期167-172,共6页 Chinese Journal of Interventional Cardiology

关键词血栓烷素11-脱氢血栓素B2 血小板高反应性阿司匹林抵抗冠状动脉粥样硬化性心脏病

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献3

1曲云霄,蒋知新,韩腾龙,王丽丽,高德禄.血小板参数及活化标志物与2型糖尿病患者颈动脉内膜中层厚度的相关性[J].实用医学杂志,2016,32(8):1250-1253. 被引量：13
2曲云霄,蒋知新,王丽丽,王菲菲,高德禄.尿11-脱氢-血栓素B_2对2型糖尿病患者冠状动脉病变的诊断价值研究[J].中国全科医学,2016,19(17):2094-2098. 被引量：8
3Luis R Lopez,Kirk E Guyer,Ignacio Garcia De La Torre,Kelly R Pitts,Eiji Matsuura,Paul RJ Ames.Platelet thromboxane(11-dehydro-Thromboxane B_2) and aspirin response in patients with diabetes and coronary artery disease[J].World Journal of Diabetes,2014,5(2):115-127. 被引量：13

二级参考文献46

1Luis R Lopez,Kirk E Guyer,Ignacio Garcia De La Torre,Kelly R Pitts,Eiji Matsuura,Paul RJ Ames.Platelet thromboxane(11-dehydro-Thromboxane B_2) and aspirin response in patients with diabetes and coronary artery disease[J].World Journal of Diabetes,2014,5(2):115-127. 被引量：13
2Tilo Grosser,Susanne Fries,John A. Lawson,Shiv C. Kapoor,Gregory R. Grant,Garret A. FitzGerald.Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin[J]. Circulation . 2013 (3)
3Jody C. Ullery,Lawrence J. Marnett.Protein modification by oxidized phospholipids and hydrolytically released lipid electrophiles: Investigating cellular responses[J]. BBA - Biomembranes . 2012 (10)
4Paul R.J. Ames,Joana R. Batuca,Ivana J. Muncy,Ignacio Garcia De La Torre,Sara Pascoe-Gonzales,K. Guyer,E. Matsuura,Luis R. Lopez.Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus[J]. Thrombosis Research . 2012 (3)
5E. MATSUURA,K. GUYER,H. YAMAMOTO,L. R. LOPEZ,K. INOUE.On aspirin treatment but not baseline thromboxane B2 levels predict adverse outcomes in patients with acute coronary syndromes[J]. Journal of Thrombosis and Haemostasis . 2012 (9)
6James P. Smith,Elias V. Haddad,Mary B. Taylor,Denise Oram,Dana Blakemore,Qingxia Chen,Olivier Boutaud,John A. Oates.Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome[J]. Hypertension . 2012 (3)
7Lillian Harboe Gon?alves,Luci Maria Sant’Ana Dusse,Ana Paula Fernandes,Karina Braga Gomes,Mirelle Oliveira Sóter,Michelle Teodoro Alves,Kathryna Fontana Rodrigues,Fernanda Rocha Freitas,Flavia Komatsuzaki,Marinez Oliveira Sousa,Adriana Aparecida Bosco,Gérson Ant?nio Pianett,Maria das Gra?as Carvalho.Urinary 11-dehydro thromboxane B 2 levels in type 2 diabetic patients before and during aspirin intake[J]. Clinica Chimica Acta . 2011 (15)
8Thomas Gremmel,Sabine Steiner,Daniela Seidinger,Renate Koppensteiner,Simon Panzer,Christoph W. Kopp.Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation[J]. Platelets . 2011 (3)
9E.SCHWEDHELM,A.BIEREND,R.MAAS,R.TRINKS,G. D.KOM,D.TSIKAS,R. H.B?GER.Redox‐generated isoprostanes are associated with residual platelet activity in aspirin‐treated patients with stable coronary heart disease[J]. Journal of Thrombosis and Haemostasis . 2010 (12)
10N. J.BREET,J. W.VAN WERKUM,H. J.BOUMAN,J. C.KELDER,J. M.TEN BERG,C. M.HACKENG.High on‐aspirin platelet reactivity as measured with aggregation‐based, cyclooxygenase‐1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events[J]. Journal of Thrombosis and Haemostasis . 2010 (10)